311 related articles for article (PubMed ID: 20435600)
1. The different effects of early and late bevacizumab (Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in rabbit limbal insufficiency.
Lin CT; Hu FR; Kuo KT; Chen YM; Chu HS; Lin YH; Chen WL
Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6277-85. PubMed ID: 20435600
[TBL] [Abstract][Full Text] [Related]
2. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.
Chen WL; Lin CT; Lin NT; Tu IH; Li JW; Chow LP; Liu KR; Hu FR
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1659-65. PubMed ID: 18997093
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
Kim TI; Kim SW; Kim S; Kim T; Kim EK
Cornea; 2008 Apr; 27(3):349-52. PubMed ID: 18362666
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model.
Papathanassiou M; Theodossiadis PG; Liarakos VS; Rouvas A; Giamarellos-Bourboulis EJ; Vergados IA
Am J Ophthalmol; 2008 Mar; 145(3):424-431. PubMed ID: 18207123
[TBL] [Abstract][Full Text] [Related]
5. Subconjunctival injection of bevacizumab in the treatment of corneal neovascularization associated with lipid deposition.
Chu HS; Hu FR; Yang CM; Yeh PT; Chen YM; Hou YC; Chen WL
Cornea; 2011 Jan; 30(1):60-6. PubMed ID: 20847676
[TBL] [Abstract][Full Text] [Related]
6. Anti-VEGF therapy (bevacizumab) for sulfur mustard-induced corneal neovascularization associated with delayed limbal stem cell deficiency in rabbits.
Kadar T; Amir A; Cohen L; Cohen M; Sahar R; Gutman H; Horwitz V; Dachir S
Curr Eye Res; 2014 May; 39(5):439-50. PubMed ID: 24215293
[TBL] [Abstract][Full Text] [Related]
7. Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model.
Avisar I; Weinberger D; Kremer I
Curr Eye Res; 2010 Feb; 35(2):108-15. PubMed ID: 20136420
[TBL] [Abstract][Full Text] [Related]
8. Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats.
Hashemian MN; Moghimi S; Kiumehr S; Riazi M; Amoli FA
Ophthalmic Res; 2009; 42(2):90-5. PubMed ID: 19546599
[TBL] [Abstract][Full Text] [Related]
9. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs.
Hurmeric V; Mumcuoglu T; Erdurman C; Kurt B; Dagli O; Durukan AH
Cornea; 2008 Apr; 27(3):357-62. PubMed ID: 18362668
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms controlling the effects of bevacizumab (avastin) on the inhibition of early but not late formed corneal neovascularization.
Chen WL; Chen YM; Chu HS; Lin CT; Chow LP; Chen CT; Hu FR
PLoS One; 2014; 9(4):e94205. PubMed ID: 24714670
[TBL] [Abstract][Full Text] [Related]
11. Characterization of corneal pannus removed from patients with total limbal stem cell deficiency.
Espana EM; Di Pascuale MA; He H; Kawakita T; Raju VK; Liu CY; Tseng SC
Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):2961-6. PubMed ID: 15326108
[TBL] [Abstract][Full Text] [Related]
12. Subconjunctival bevacizumab for corneal neovascularization.
Zaki AA; Farid SF
Acta Ophthalmol; 2010 Dec; 88(8):868-71. PubMed ID: 19519730
[TBL] [Abstract][Full Text] [Related]
13. The effect of subconjunctival suramin on corneal neovascularization in rabbits.
Lee HS; Chung SK
Cornea; 2010 Jan; 29(1):86-92. PubMed ID: 19907290
[TBL] [Abstract][Full Text] [Related]
14. Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization.
Qian CX; Bahar I; Levinger E; Rootman D
Cornea; 2008 Oct; 27(9):1090-2. PubMed ID: 18812781
[TBL] [Abstract][Full Text] [Related]
15. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn.
Yoeruek E; Ziemssen F; Henke-Fahle S; Tatar O; Tura A; Grisanti S; Bartz-Schmidt KU; Szurman P;
Acta Ophthalmol; 2008 May; 86(3):322-8. PubMed ID: 17995975
[TBL] [Abstract][Full Text] [Related]
16. Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats.
Hashemian MN; Z-Mehrjardi H; Moghimi S; Tahvildari M; Mojazi-Amiri H
Ophthalmic Res; 2011; 46(1):50-4. PubMed ID: 21212709
[TBL] [Abstract][Full Text] [Related]
17. Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy.
Oh JY; Kim MK; Wee WR
Cornea; 2009 Oct; 28(9):1070-3. PubMed ID: 19724199
[TBL] [Abstract][Full Text] [Related]
18. Topical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model.
Öner V; Küçükerdönmez C; Akova YA; Çolak A; Karalezli A
Ophthalmic Res; 2012; 48(3):118-23. PubMed ID: 22538642
[TBL] [Abstract][Full Text] [Related]
19. Subconjunctival bevacizumab for corneal neovascularization.
Doctor PP; Bhat PV; Foster CS
Cornea; 2008 Oct; 27(9):992-5. PubMed ID: 18812760
[TBL] [Abstract][Full Text] [Related]
20. The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization.
Habot-Wilner Z; Barequet IS; Ivanir Y; Moisseiev J; Rosner M
Acta Ophthalmol; 2010 Dec; 88(8):862-7. PubMed ID: 19549103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
